GlassScriptPhysician profile
Steven Glenn Clemenson
NPI 1174541874
$572.32
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $238 · 2021: $103.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $121.13 | 2019-2021 | |
| Esperion Therapeutics, INC. | $80.57 | 2020 | |
| Merck Sharp & Dohme LLC | $69.18 | 2019-2020 | |
| Nevro Corp. | $40.70 | 2020 | |
| Lilly USA, LLC | $27.98 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.67 | 2020 | |
| Abbvie INC. | $22.03 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.60 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.30 | 2019 | |
| Abbott Laboratories | $17.93 | 2021 | |
| Acadia Pharmaceuticals INC | $16.68 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.38 | 2019 | |
| Amarin Pharma, INC. | $15.33 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.86 | 2019 | |
| Boston Scientific Corporation | $14.20 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $13.17 | 2020 | |
| Tactile Systems Technology INC | $12.61 | 2019 | |
| Antares Pharma, INC. | $12.45 | 2019 | |
| Alexion Pharmaceuticals, INC. | $11.55 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Clemenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.